Securian Asset Management Inc. Has $563,000 Stock Holdings in Medpace Holdings, Inc. $MEDP

Securian Asset Management Inc. trimmed its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 9.2% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,795 shares of the company’s stock after selling 182 shares during the period. Securian Asset Management Inc.’s holdings in Medpace were worth $563,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of MEDP. Mawer Investment Management Ltd. acquired a new position in shares of Medpace during the 1st quarter worth about $212,131,000. Vulcan Value Partners LLC boosted its stake in shares of Medpace by 221.6% during the 1st quarter. Vulcan Value Partners LLC now owns 325,916 shares of the company’s stock worth $99,159,000 after buying an additional 224,578 shares during the last quarter. Jacobs Levy Equity Management Inc. boosted its stake in shares of Medpace by 675.8% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 121,464 shares of the company’s stock worth $37,009,000 after buying an additional 105,807 shares during the last quarter. Invesco Ltd. boosted its stake in shares of Medpace by 9.4% during the 1st quarter. Invesco Ltd. now owns 1,186,768 shares of the company’s stock worth $361,596,000 after buying an additional 102,015 shares during the last quarter. Finally, Northern Trust Corp boosted its stake in shares of Medpace by 36.0% during the 1st quarter. Northern Trust Corp now owns 337,489 shares of the company’s stock worth $102,830,000 after buying an additional 89,347 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Medpace Stock Up 1.4%

Shares of MEDP stock opened at $605.20 on Friday. The firm has a 50 day moving average price of $503.13 and a two-hundred day moving average price of $391.27. The company has a market capitalization of $17.00 billion, a PE ratio of 42.32, a price-to-earnings-growth ratio of 3.53 and a beta of 1.40. Medpace Holdings, Inc. has a 12-month low of $250.05 and a 12-month high of $625.00.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Wednesday, October 22nd. The company reported $3.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.50 by $0.36. The firm had revenue of $659.90 million during the quarter, compared to the consensus estimate of $640.49 million. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The business’s revenue for the quarter was up 23.7% compared to the same quarter last year. During the same period last year, the business posted $3.01 earnings per share. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. As a group, research analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Insider Activity at Medpace

In other Medpace news, CEO August J. Troendle sold 36,196 shares of the firm’s stock in a transaction that occurred on Friday, August 29th. The shares were sold at an average price of $475.90, for a total transaction of $17,225,676.40. Following the completion of the sale, the chief executive officer directly owned 925,799 shares in the company, valued at $440,587,744.10. This trade represents a 3.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Cornelius P. Mccarthy III sold 1,662 shares of the firm’s stock in a transaction that occurred on Tuesday, August 19th. The stock was sold at an average price of $465.04, for a total transaction of $772,896.48. Following the sale, the director owned 10,197 shares of the company’s stock, valued at $4,742,012.88. This trade represents a 14.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 107,465 shares of company stock valued at $49,720,216. 20.30% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. Wall Street Zen upgraded shares of Medpace from a “hold” rating to a “buy” rating in a research note on Saturday. Rothschild & Co Redburn downgraded shares of Medpace from a “buy” rating to a “neutral” rating and raised their target price for the company from $342.00 to $474.00 in a research note on Wednesday, September 3rd. Mizuho raised their target price on shares of Medpace from $575.00 to $655.00 and gave the company an “outperform” rating in a research note on Friday. Deutsche Bank Aktiengesellschaft raised their target price on shares of Medpace from $270.00 to $430.00 and gave the company a “hold” rating in a research note on Wednesday, July 23rd. Finally, Cowen reiterated a “sell” rating on shares of Medpace in a research note on Friday. Two investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and four have given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Reduce” and an average price target of $464.00.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.